Esperion

[anonymous]

Esperion's prospects all all hinged on label expansion and resolving the overhang with the milestone dispute with DSE for the much needed $300MM cash infusion. Right now our hands our tied given the contraints of the label. Relaunch with relabel in 1H2024.

More double talk from management. They can't face the fact that this has been a failure of epic proportions. Too many "what ifs". This isn't going to have a happy ending.

 

[anonymous]

More double talk from management. They can't face the fact that this has been a failure of epic proportions. Too many "what ifs". This isn't going to have a happy ending.

And outsiders can only look in and drool at the opportunities ahead. We are winning.

 

[anonymous]

We had a real rough few weeks. Wall St not impressed with Esperion. This hasn't gone as planned and management has its pants down around its ankles as they fumble through 2023. The money burn continues as Eaperion waits with their cup in hand to try and get 300 million out of DS. DS says the outcomes data sucked and didn't meet pre-arranged efficacy endpoints. At some point Esperion will have to make a profit and it looks like that's a pipedream.

 

[anonymous]

And outsiders can only look in and drool at the opportunities ahead. We are winning.

FJB drools.

 

[anonymous]

$1.29. Just let that sink in for a minute all you Esperion cheerleaders.

 

[anonymous]

$1.29. Just let that sink in for a minute all you Esperion cheerleaders.

And you’d be a fool not to buy!!

 

[anonymous]

The shorts are in play again. Watch and learn Gordon Geeko. This is a stock to play the short market.

 

[anonymous]

Go long on this. Make $$

 

[anonymous]

If you shorted it this am then you made money.

 

[anonymous]

We are starting to pick up some recommendations as the expectations are being raised based on the recent progress. The management team has positioned us for quite a spate of positive catalysts over the next 12 months, and this can help drive share price quite significantly.

 

[anonymous]

We are starting to pick up some recommendations as the expectations are being raised based on the recent progress. The management team has positioned us for quite a spate of positive catalysts over the next 12 months, and this can help drive share price quite significantly.

Yep management is just like Houdini and David Blaine. Make the stock climb from $1.40 to 78.00 which it was 3 years ago. This management team is the worst in the industry. The sheer incompetence of these people is staggering.

 

[anonymous]

We are starting to pick up some recommendations as the expectations are being raised based on the recent progress. The management team has positioned us for quite a spate of positive catalysts over the next 12 months, and this can help drive share price quite significantly.

Lol
What is this word salad ?
I'll take the Italian Dressing on this.

 

[anonymous]

We are starting to pick up some recommendations as the expectations are being raised based on the recent progress. The management team has positioned us for quite a spate of positive catalysts over the next 12 months, and this can help drive share price quite significantly.

Yes they've done a real bang up job. The stock has been responding negatively as usual as Esperion basks in the bowels of the NYSE. This is a bottom dweller stock. Just keep shorting the stock!!

 

[anonymous]

Yes they've done a real bang up job. The stock has been responding negatively as usual as Esperion basks in the bowels of the NYSE. This is a bottom dweller stock. Just keep shorting the stock!!

This advice has been spot on.

The only way to make money seems to be shorting.

Remember when stock was $78.00 ?
Now a buck and spare change.

 

[anonymous]

This advice has been spot on.

The only way to make money seems to be shorting.

Remember when stock was $78.00 ?
Now a buck and spare change.

Okay, Karen Orman.

 

[anonymous]

ESPR = $ 1.00 share

Coming soon to the Scientific Hired, High Tenured Customer Facing Team. And Lipid Trained Experts.

 

[anonymous]

ESPR = $ 1.00 share

Coming soon to the Scientific Hired, High Tenured Customer Facing Team. And Lipid Trained Experts.

Actually stock finished at 99 cents. Did get as low as 83 cents yesterday.

 

[anonymous]

We are starting to pick up some recommendations as the expectations are being raised based on the recent progress. The management team has positioned us for quite a spate of positive catalysts over the next 12 months, and this can help drive share price quite significantly.

Looks youbwrre spot on with your nonsense statement based on yesterday's stock performance. Again you show your business acumen.

 

[anonymous]

The loose change I've in my pocket is worth more than what this stock is worth. 99cents!!! Bravo Esperion reps and management!! What an awesome launch of this product . BA should be renamed BM for Bowel Movement.

 

[anonymous]

Biotech is likely to slip further in the coming weeks, with the acceptance of higher rates chewing at the high beta stocks like ESPR. The business remains intact with a bright future as the outcomes data should result in both a large check from the Japanese and a label change stateside. We’ve all seen the rise in share price when events like these materialize, it’s our time to shine in the sun!